New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
10:25 EDTBSX, BSX, LLY, LLY, LH, LH, GEVA, GEVA, ACT, ACT, Q, Q, BIO, BIO, HSIC, HSIC, ALOG, ALOG, SIAL, SIAL, WMGI, WMGI, AGIO, AGIO, OPHT, OPHTJPMorgan to host a conference
32nd Annual Healthcare Conference is being held in San Francisco on January 13-16 with webcasted company presentations to begin on January 13 at 10:30 am; not all presentations may be webcasted. Webcast Link
News For OPHT;AGIO;WMGI;SIAL;ALOG;HSIC;BIO;Q;ACT;GEVA;LH;LLY;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 9, 2016
08:20 EDTBSXBoston Scientific should move higher on CMS decision, says Leerink
Subscribe for More Information
08:06 EDTBSXCMS decision removes major overhang on Boston Scientific, says RBC Capital
Subscribe for More Information
07:24 EDTBSXBoston Scientific has positive read through from CMS decision, says Stifel
Subscribe for More Information
February 8, 2016
19:38 EDTBSXBoston Scientific announces Medicare will cover Watchman LAAC Device
Subscribe for More Information
07:44 EDTQQuintiles added to Franchise Pick List at Jefferies
Jefferies analyst David Windley added Quintiles to his firm's Franchise Pick List saying the company has more "large, ingrained relationships" than any other Contract Research Organization despite the underperformance of the shares. The analyst has a Buy rating on the stock with an $82 price target.
07:32 EDTAGIOAgios Pharmaceuticals appoints Steve Hoerter as Chief Commercial Officer
Agios Pharmaceuticals announced the appointment of Steve Hoerter to the newly created position of chief commercial officer, effective February 16. Hoerter has more than 20 years of global pharmaceutical and biotechnology experience, most recently having served as executive vice president and chief commercial officer at Clovis Oncology, Inc. as well as previous senior commercial roles at Genentech and Roche.
06:28 EDTLLYPharma trade group rolls out ad campaign aimed at lawmakers, WSJ says
The pharmaceutical industry is launching a new ad campaign with the intention of improving its reputation with lawmakers in an effort to lobby against drug price restrictions, the Wall Street Journal reports. The industry's biggest trade group the Pharmaceutical Research and Manufacturers of America, or PhRMA, says it plans to spend several million dollars this year, and 10% more than it spent last year, on digital, radio, and print advertisements that highlight the sector's role in developing new drugs and advancing medical science, the report says. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link
February 5, 2016
07:34 EDTBSXBoston Scientific 2016 results poised to beat expectations, says RBC Capital
Subscribe for More Information
07:12 EDTHSICHenry Schein to acquire majority interest in Brazilian Dental Cremer
Subscribe for More Information
06:36 EDTBSXBoston Scientific post-earnings selloff overdone, says Leerink
Subscribe for More Information
February 4, 2016
14:53 EDTBSXBoston Scientific weakness a buying opportunity, says BofA/Merrill
11:21 EDTBSXOptions with increasing call volume; FMC HST XME RIO BHP PAY DNDK BSX ALLY SWFT
10:20 EDTBSXHigh option volume stocks: EPC DK DNKN TTWO AVT VHC RL ZBH BSX AGCO
Subscribe for More Information
06:42 EDTBSXBoston Scientific reports Q4 adjusted EPS 26c, consensus 25c
Reports Q4 revenue $1.98B, consensus $1.99B.
February 3, 2016
14:48 EDTBSXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Philip Morris (PM), consensus 81c... AstraZeneca (AZN), consensus 88c... Occidental Petroleum (OXY), consensus (12c)... ConocoPhillips (COP), consensus (65c)... Cigna (CI), consensus $1.80... Intercontinental Exchange (ICE), consensus $3.01... Boston Scientific (BSX), consensus 25c... Charter Communications (CHTR), consensus (12c)... Ralph Lauren (RL), consensus $2.13... Dunkin' Brands (DNKN), consensus 50c... GrubHub (GRUB), consensus 14c... Level 3 (LVLT), consensus 53c... AmerisourceBergen (ABC), consensus $1.25... Cummins (CMI), consensus $2.11.
07:07 EDTHSICHenry Schein completes acquisition of RxWorks
Subscribe for More Information
February 1, 2016
08:32 EDTALOGAnalogic launches ultrasound telehealth services with Oncura Partners
Subscribe for More Information
06:18 EDTLLYTransition Therapeutics announces results from Phase 2 clinical study of TT401
Subscribe for More Information
06:11 EDTLLYTransition Therapeutics reports results from Phase 2 clinical study of TT401
Subscribe for More Information
January 29, 2016
05:20 EDTLLYEli Lilly, Adocia initiate Phase 1b study of BioChaperone Lispro U100
Adocia and Eli Lilly announced the initiation of a Phase 1b clinical trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Lilly. This formulation uses Adocia's proprietary technology, BioChaperone, which is designed to enable the acceleration of insulin absorption. The study, under the Adocia-Lilly partnership, aims to compare the pharmacokinetic and pharmacodynamic profiles of BioChaperone Lispro to that of Humalog in 15 healthy Japanese subjects placed under euglycemic clamp.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use